Research Article
Formulation Development and Stability Studies of Norfloxacin Extended-Release Matrix Tablets
Table 3
Assay results of accelerated stability test.
| Formulation | Time zero | After 6 months | ā | ā | Blister | Without blister | Uncoated (%) | Coated (%) | Uncoated (%) | Coated (%) | Uncoated (%) | Coated (%) |
| HPMC K100LV 20% | 101.98 | 101.09 | 101.16 | 101.51 | 102.03 | 101.18 | HPMC K100LV 30% | 101.47 | 101.81 | 101.87 | 103.01 | 100.87 | 101.74 | HPMC K4M 20% | 101.45 | 100.42 | 100.44 | 102.98 | 101.92 | 101.08 | HPMC K4M 30% | 100.88 | 99.31 | 99.12 | 99.45 | 99.91 | 98.09 | PEO N60K 20% | 102.06 | 101.72 | 102.89 | 98.47 | 101.44 | 100.26 | PEO N60K 30% | 99.43 | 99.92 | 98.49 | 99.05 | 99.44 | 99.03 | PEO 301 20% | 99.48 | 99.35 | 101.24 | 97.51 | 101.75 | 100.31 | PEO 301 30% | 99.71 | 100.50 | 99.03 | 100.49 | 100.61 | 100.36 |
|
|